drugset
drugset / Trial / NCT07253207

Efficacy and Safety Study of Levomilnacipran Hydrochloride Extended-Release Capsules in Major Depressive Disorder

NCT07253207 ↗

Phase 3 Completed 392 enrolled Zhejiang Huahai Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is using Duloxetine Hydrochloride Enteric Capsules as the positive control, to evaluate the efficacy and safety of Levomilnacipran Hydrochloride Extended-Release Capsules in patients with Major Depressive Disorder (MDD).

Timeline

Start
2024-10-17
Primary completion
2025-06-13
Completion
2025-07-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator Duloxetine Small molecule 60 mg Oral
Subject Levomilnacipran Small molecule 40 mg Oral
Subject Levomilnacipran Small molecule 80 mg Oral
Subject Levomilnacipran Small molecule 120 mg Oral

Indications

major depressive disorder